ABSTRACT
Objective Using a pandemic influenza model modified for COVID-19, this study investigated the degree of control over pre-symptomatic transmission that common non-pharmaceutical interventions (NPIs) would require to reduce the spread in long-term care facilities.
Methods We created a stochastic compartmental SEIR model with Poisson-distributed transition states that compared the effect of R0, common NPIs, and isolation rates of pre-symptomatic carriers primarily on attack rate, peak cases, and timing in a 200-resident nursing home. Model sensitivity was assessed with 1st order Sobol’ indices.
Results The most rigorous NPIs decreased the peak number of infections by 4.3 and delayed the peak by 9.7 days in the absence of pre-symptomatic controls. Reductions in attack rate were not likely, even with rigorous application of all defined NPIs, unless pre-symptomatic carriers were identified and isolated at rates exceeding 76%. Attack rate was most sensitive to the pre-symptomatic isolation rate (Sobol’ index > 0.7) and secondarily to R0.
Conclusions Common NPIs delayed and reduced epidemic peaks. Reducing attack rates ultimately required efficient isolation of pre-symptomatic cases, including rapid antigen tests on a nearly daily basis. This must be accounted for in testing and contact tracing plans for group living settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by a Seed Fund Award 2020-0000000022 from CITRIS and the Banatao Institute at the University of California. No third-party support was provided for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mathematical modeling paper; exempt from IRB review by the UC Davis Office of Research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: None declared.
Source of Funding: This research was supported by a Seed Fund Award 2020-0000000022 from CITRIS and the Banatao Institute at the University of California.
Data Access: The full MATLAB code and all required materials to replicate the simulations from this mathematical modeling paper are publicly available at https://doi.org/10.5281/zenodo.4073575
Data Availability
The full MATLAB code and all required materials to replicate the simulations from this mathematical modeling paper are publicly available at https://doi.org/10.5281/zenodo.4073575
LIST OF ABREVIATIONS
- COVID-19
- Coronavirus Disease 2019
- EUA
- Emergency Use Act
- FDA
- Food and Drug Administration
- GSA
- Generalized Sensitivity Analysis
- LTCF
- Long-Term Care Facility
- NPI
- Non-Pharmaceutical Intervention
- PCR
- Polymerase Chain Reaction
- PPE
- Personal Protective Equipment
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- SEIR
- Susceptible Exposed Infected Recovered
- WHO
- World Health Organization
